67 results
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of real
6-K
EX-99.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
BioLineRx’s collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
efforts to develop the licensed technology in accordance with a specified development plan, including meeting certain specified diligence goals.
Each … could directly affect our ability to attain our operating goals on schedule and on budget.
The market prices of our ordinary shares and ADSs
20-F/A
2023 FY
EX-2.1
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
BioLineRx Ltd.
Name of Company
The name of the Company is BioLineRx Ltd.
Goals of the Company
The goal of the Company is to engage in any lawful … in the Company.
Any Request to Convene must specify the goals for whose purpose the meeting is to be convened, and shall be signed by those requesting
6-K
EX-99
n0hw5vn9tqyi6rcy5i1
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
20b18ocf4 td
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
u9d1z0wtvq
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
3yw4wwi2 xj5
16 Feb 24
Current report (foreign)
7:07am
6-K
EX-99
olgq8ew6gg0ycu
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
pih6zsi4uo5z4s7e
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
0li61map73i rrsevka1
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
sx1plyhixu6
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
gb3p1 tzhmi
15 Sep 22
Current report (foreign)
8:39am
6-K
EX-99
9kla 1jv6
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm